KR100422760B1 - Thermotropic liquid crystal polymer microcapsules and process for preparing the same, and cosmetic composition containing the thermotropic liquid crystal polymer microcapsules - Google Patents

Abstract

The present invention relates to a thermotropic liquid crystal polymer microcapsules and a method for preparing the same, and a cosmetic composition containing the liquid crystal polymer microcapsules. More specifically, the phase behavior of the thermotropic liquid crystal in the polymer phase due to the phase separation of the polymer and the liquid crystal It can be used as an additive, and furthermore, the visual effect of the liquid crystal can be directly confirmed by the naked eye, and thus it can be used as an additive having a visible effect in the cosmetic composition, and a liquid crystal capable of stabilizing the active substance by containing other functional active substances in the liquid crystal. It relates to a polymer microcapsules and a method for preparing the same.

Description

Thermotropic liquid crystal polymer microcapsules and process for preparing the same, and cosmetic composition containing the thermotropic liquid crystal polymer microcapsules}

The present invention relates to a thermotropic liquid crystal polymer microcapsules and a method for preparing the same, and a cosmetic composition containing the liquid crystal polymer microcapsules. More specifically, the phase behavior of a thermotropic liquid crystal in a polymer phase due to phase separation of a polymer and a liquid crystal Liquid crystal polymer that can be displayed as it is, and furthermore, the visual effect of the liquid crystal can be directly identified and can be used as an additive which shows a visible effect in the cosmetic composition, and liquid crystal polymer capable of stabilizing the active substance by containing other functional active substances in the liquid crystal. It relates to a microcapsule and a method for preparing the same.

Liquid crystals are widely used for displays of electronic materials such as projectors, computers, and televisions by utilizing variations in the arrangement of electric fields. In addition, when the liquid crystal is contained in the cosmetics, the stratum corneum layer defense function is increased, the skin moisturizing and softening effect is increased, and in the case of some liquid crystals, structural regularity is expressed to scatter the light to show the color, which makes the product unusual in appearance. As it can provide, it is used widely in cosmetics field.

Conventionally, such liquid crystals are used by encapsulating liquid crystals with polymers for the purpose of protecting against contamination, oxidation, radiation, and the like, and to provide liquid crystal materials having new functions. In addition, many studies have been made regarding encapsulation. have.

Specifically, Japanese Patent Laid-Open No. 61-502128 discloses a method in which a liquid crystal and a thermosetting resin are mixed and the resin in the mixture is cured to form liquid crystal particles in order to be separated from the liquid crystal. U.S. Pat.Nos. 4285720, 4155741 and 4046741 also disclose methods for making capsules by interfacial polymerization of polyisocyanates as intermediates for forming polyurea capsules.

However, these conventional methods have a problem in that the liquid crystal is not separated from the polymer phase but dispersed in the polymer, so that the inherent behavior (alignment of the liquid crystal) of the liquid crystal cannot be observed.

In addition, in the case of thermotropic liquid crystals that can be applied to smart systems that respond to external environments, the behavior of liquid crystals can be added to solvents or shifted to hydrophobic phases because the behavior of liquid crystals is changed by environmental changes such as temperature. Encapsulation itself is difficult because it disappears due to dilution.

Thus, the present inventors have prepared a capsule in Thermotropic method of the liquid crystal was studied encapsulation method of a liquid crystal can still exhibit a liquid crystal behavior in the polymer, and the polymerization as a result, cholesterol-based thermotropic liquid crystal together with the monomer in-situ suspension As the polymerization progresses, the liquid crystal material undergoes phase separation in the polymer dispersion due to the decrease in compatibility between the liquid crystal material and the polymer phase, and thus the polymer can obtain capsule-shaped particles encapsulating the thermotropic liquid crystal. The present invention has been accomplished by discovering that it may appear as is.

Accordingly, an object of the present invention is to provide a thermotropic liquid crystal polymer capsule which can exhibit the behavior of liquid crystal.

Another object of the present invention is to provide a method for producing the capsule.

Still another object of the present invention is to provide a cosmetic composition containing the capsule described above.

Figure 1a is an optical micrograph of the capsule prepared in Example 1 of the present invention (X500).

Figure 1b is a polarization micrograph of the capsule prepared in Example 1 of the present invention (X500).

Figure 2a is an optical micrograph of the capsule prepared in Example 2 of the present invention (X500).

Figure 2b is a polarization micrograph of the capsule prepared in Example 2 of the present invention (X500).

Figure 3a is an optical micrograph of the capsule prepared in Comparative Example 2 of the present invention (X500).

3b is a polarization micrograph of the capsule prepared in Comparative Example 2 of the present invention (X500).

Figure 4a is an optical micrograph of the capsule prepared in Comparative Example 3 of the present invention (X500).

Figure 4b is a polarizing microscope picture of the capsule prepared in Comparative Example 3 of the present invention (X500).

In order to achieve the above object, the thermotropic liquid crystal polymer capsule according to the present invention is characterized by being prepared by suspension polymerization of a thermotropic liquid crystal with a monomer. Specifically, after dissolving the thermotropic liquid crystal and the monomer in a solvent, adding an initiator; Adding the solution to an aqueous phase containing a dispersion stabilizer and then emulsifying to obtain an emulsion; And adding a polymerization inhibitor to the emulsion and then suspending polymerization to obtain a thermotropic liquid crystalline polymer capsule.

Hereinafter, the present invention will be described in more detail.

The thermotropic liquid crystal polymer capsule provided by the present invention is a form in which a polymer encapsulates a liquid crystal, and thus the behavior of the liquid crystal, that is, the orientation of the liquid crystal, can be expressed as it is, and a visible effect can be obtained. In addition, the thermotropic liquid crystal polymer capsule of the present invention can be applied to a smart drug system having a temperature dependency because the behavior of the liquid crystal is exhibited according to the temperature. That is, when the temperature rises, the liquid crystal is not exhibited and the fluidity is enhanced, so that the drug may be released quickly. On the other hand, since the release of the drug may be delayed due to the liquid crystal at low temperature, the drug may be applied to the drug system. In addition, the liquid crystal polymer capsule of the present invention may be used as a stabilizing agent because the active material is double stabilized by the liquid crystal and the polymer when the active material is trapped in the liquid crystal.

Hereinafter, the method of manufacturing the thermotropic liquid crystal polymer capsule of the present invention will be described in detail for each step.

(1) After dissolving the thermotropic liquid crystal and monomer in a solvent, adding an initiator.

The liquid crystal used in the present invention is a thermotropic liquid crystal, and a cholesterol-based liquid crystal is used. Cholesterol-based liquid crystals are cholesterol liquid crystals or cholesteryl derivatives, and specific examples thereof include cholesteryl octanoate, cholesteryl nonanoate, cholesteryl oleyl carbonate, and cholesteryl isostearyl carbonate.

This cholesterol liquid crystal can exhibit various colors depending on the temperature or the angle of light, and it is already known as a cosmetic raw material because it is harmless to the human body.

The amount of the liquid crystal used is added in an amount of 30 to 50% by weight based on the total capsule particles. This is because when the liquid crystal is added at less than 30% by weight, the behavior of the liquid crystal cannot be observed, and when it exceeds 50% by weight, no capsule is formed.

The monomer used in the present invention is not particularly limited as long as it is capable of radical polymerization, and specifically, styrene, p- or m-methylstyrene, p- or m-ethylstyrene, p- or m-chlorostyrene, p Or m-chloromethylstyrene, styrenesulphonic acid, p- or m- or t-butoxystyrene, methyl (meth) acrylate, ethyl (meth) acrylate, propyl (meth) acrylate, n-butyl ( Meta) acrylate, isobutyl (meth) acrylate, t-butyl (meth) acrylate, 2-ethylhexyl (meth) acrylate, n-octyl (meth) acrylate, lauryl (meth) acrylate, ste Aryl (meth) acrylate, 2-hydroxyethyl (meth) acrylate, polyethylene glycol (meth) acrylate, methoxy polyethylene glycol (meth) acrylate, glycidyl (meth) acrylate, dimethylaminoethyl (meth ) Acrylate, diethyl Minoethyl (meth) acrylate, vinyl acetate, vinyl propionate, vinyl butyrate, vinyl ether, allyl butyl ether, allyl glycidyl ether, (meth) acrylic acid, unsaturated carboxylic acids such as maleic acid, alkyl (meth) acrylamide, (Meth) acrylonitrile etc. can be used in mixture of 1 or more types. The amount of the monomer is added in an amount of 70 to 50% by weight based on the total capsule particles. This is because the capsule is not prepared when the monomer is added in less than 50% by weight, and the behavior of the liquid crystal cannot be observed when it exceeds 70% by weight.

Solvents are those that can dissolve the liquid crystals and monomers described above, and those having a low boiling point and little mixing with water are used. Specifically, halogenated alkanes such as chloromethane, dichloromethane, chloroform, tetrachloromethane, dichloroethane, ethyl acetate, diethyl ether, cyclohexane, benzene, toluene and the like can be used.

When the liquid crystal and the monomer are dissolved in a solvent, ultrasonic waves may be dissolved to uniformly dissolve the liquid crystal and the monomer.

On the other hand, an initiator is added to the solution to advance the polymerization reaction.

Initiators used in the present invention include benzoyl peroxide, lauryl peroxide, o-chlorobenzoyl peroxide, o-methoxybenzoyl peroxide, t-butylperoxy-2-ethylhexanoate, t-butylperoxy Peroxides such as isobutylate, 1,1,3,3-tetramethylbutylperoxy-2-ethylhexanoate, dioctanoyl peroxide, didecanoyl peroxide, and 2,2-azobisisobuty Azo compounds such as ronitrile, 2,2-azobis (2-methylbutyronitrile), 2,2-azobis (2,4-dimethylvaleronitrile) and the like are used. The amount of the initiator is preferably 1 to 2% by weight relative to the total monomers considering the effective starting efficiency. In other words, it is possible to polymerize at a concentration of less than 1% by weight, but to obtain a degree of polymerization of 90% or more, a long-term polymerization time is required. This is because there is a problem of forming a polymer.

In addition, a crosslinking agent may be further added in this step to enhance the physical properties of the polymer capsule. The type of crosslinking agent is not particularly limited as long as it is capable of radical polymerization, but specifically, divinylbenzene, 1,4-divinyloxybutane, divinylsulphone, diallyl phthalate, diallyl acrylamide, triallyl (iso) Allyl compounds such as cyanurate and triallytrimellitate, (poly) ethylene glycol di (meth) acrylate, (poly) propylene glycol di (meth) acrylate, pentaerythritol tetra (meth) acrylate , Pentaaryl tritol tri (meth) acrylate, pentaaryl tritol di (meth) acrylate, trimethylol propane tri (meth) acrylate, dipentaerythritol hexa (meth) acrylate, ifenta (Poly) alkylene glycol di (meth) acrylates, such as a ryl tritol penta (meth) acrylate and a glycerol tri (meth) acrylate, etc. can be used. It is preferable to use the usage-amount in the range of 0.1 to 0.3 weight% with respect to a polymer total amount.

(2) adding the solution to an aqueous phase containing a dispersion stabilizer and then emulsifying to obtain an emulsion:

The dispersion stabilizer used in the present invention is a polymer that can be dissolved in an aqueous phase, and specifically, gelatin, starch, hydroxyethyl cellulose, carboxymethyl cellulose, polyvinylpyrrolidone, polyvinyl alkyl ether, polyvinyl alcohol, poly Dimethylsiloxane / polystyrene block copolymer, etc. are included, and the amount of the polymer capsule produced during the dispersion polymerization is preferably 1 to 5% by weight relative to the total reactants to the extent that the polymer capsule generated during the dispersion polymerization process can suppress deposition due to gravity or aggregation between particles. . This is because, if less than 1% by weight, the stabilization ability is sharply lowered, and if the content exceeds 5% by weight, not only the viscosity of the system is increased, but also the stabilization ability reaches an equilibrium, which does not contribute to stabilization.

(3) adding a polymerization inhibitor to the emulsion, followed by suspension polymerization to obtain a thermotropic liquid crystalline polymer capsule.

Suspension polymerization should be carried out only in the emulsion. In the reaction step, the emulsion particles are dispersed in the aqueous phase and then suspended in the aqueous phase, so that the reaction is carried out by the initiator in the aqueous phase to produce too small capsule particles, and also to efficiently form the capsule particles. Will not be. Therefore, a polymerization inhibitor is used to prevent polymerization in the water phase.

The type of polymerization inhibitor to be used in the present invention is not particularly limited as long as it can be dissolved in an aqueous solution. Specifically, inorganic substances such as hydroxylamine, hydrazine, sodium nitrite and potassium nitrite, hydroquinone and hydroquinone Organic substances such as monomethyl ether and pyrocatechol. The amount used is preferably 0.01% by weight or less based on the total reactants. This is because on the contrary, the starting efficiency is lowered and there is a polymerization inhibiting effect.

Suspension polymerization is carried out in a conventional manner in the art.

On the other hand, since the liquid crystal produced by the above method is hydrophobic, the behavior of the liquid crystal cannot be observed in the aqueous solution. Therefore, in the present invention, the polymer capsules are hydrated to visually check the behavior of the liquid crystal even in the aqueous solution. As a result, the hydrated capsules can be used as additives that have a visible effect in water-soluble cosmetics.

Methods for hydrating capsules include adding ionic monomers and adding hydrophilic monomers.

Specifically, cationic monomers such as aminoalkyl (meth) acrylates or anionic monomers such as acrylic acid, (meth) acrylic acid, maleic acid, fumaric acid, itaconic acid and sulfonic acid are introduced in an amount of 10 to 30% by weight. There is a method to hydrate.

There is also a method of adding and hydrating hydrophilic monomers such as acrylonitrile, (meth) acrylonitrile, acrylamide, and (meth) acrylamide in an amount of 10 to 50% by weight.

The thermotropic liquid crystal polymer capsule of the present invention can also be used as a stabilizing agent for oil-soluble active substances because other functional active ingredients can be contained in the liquid crystal phase. That is, most of the useful active materials are rapidly reduced efficacy when exposed to the external environment such as light, heat, water. In particular, in the case of the active ingredient to impart functionality to the cosmetic formulation is to be denatured by the surfactant, water, oil components, etc. present in the formulation it should be able to block the various stimuli, the active ingredient in the capsule of the present invention When trapped, cholesterol structurally forms a spherical liquid crystal, and since the outer shell is enclosed by a polymer secondary, there is a double stabilizing effect to stabilize the active substance.

Such functionally active substances include retinol, retinyl acetate, retinyl palmitate, α-tocopherol, tocopherol acetate, tocopherylolinate, tocopheryl nicotinate, linoleic acid, coenzyme Q-10, resveratrol, plants Extracting essential oils.

Hereinafter, the present invention will be described in more detail with reference to Examples and Comparative Examples, but the present invention is not limited thereto.

<Example 1>

30% by weight of cholesteryl nonanoate and 70% by weight of methyl methacrylate monomer were uniformly dissolved by ultrasonic irradiation in 20 ml of methylene chloride. At this time, 1% by weight of 2,2'-azobis (2-methylbutyronitrile) relative to the monomer was added as an initiator. Then, the solution was added to an aqueous solution in which 1.5% of polyvinyl alcohol with saponification degree 87-89% was dissolved, and then emulsified at 5,000 rpm shear stress for 5 minutes. This emulsion was placed in a reactor heated to 60 ° C., 0.01% by weight of Sodium Denitrite was added and then polymerized for 4 hours. After the polymerization was completed, the remaining organic solvent was evaporated under reduced pressure, filtered, washed with water, and then repeated several times, followed by drying in a vacuum oven to obtain a powdered cholesterol liquid crystal polymer capsule.

<Example 2>

It was prepared in the same manner as in Example 1 except that 0.3 wt% of ethylene glycol dimethyl ether relative to the monomer was dissolved in methylene chloride as a crosslinking agent.

Comparative Example 1

A cholesteryl nonanoate liquid crystal was used in the same manner as in Example 2 except that no liquid crystal was used.

Comparative Example 2

A cholesteryl nonanoate liquid crystal was prepared in the same manner as in Example 2 except that the liquid crystal was used in an amount of 10% by weight.

Comparative Example 3

It was prepared in the same manner as in Example 2 except that the crosslinking agent was used in an amount of 1.0% by weight based on the monomers.

<Example 3>

A liquid crystal polymer capsule was obtained in the same manner as in Example 2, except that 15 wt% of (meth) acrylic acid was introduced to the methyl methacrylate monomer during polymerization.

<Example 4>

A cholesterol liquid crystal polymer capsule was obtained in the same manner as in Example 2 except that 20% by weight of vinyl acetate was introduced into the methyl methacrylate monomer during polymerization.

Example 5

The polymerization was carried out in the same manner as in Example 2, except that 30 wt% acrylonitrile was introduced into the methyl methacrylate monomer to obtain a cholesterol liquid crystal polymer capsule.

<Example 6>

In order to apply the cholesterol liquid crystal polymer capsule prepared in Example 1 as a stabilizing agent for the oil-soluble active substance, the active substance was collected in the liquid crystal polymer capsule using the solute co-diffusion method disclosed in Korean Patent No. 2000-58991.

Specifically, 0.5 g of retinol as an active substance was completely dissolved in 20 ml of methylene chloride, and then added to 80 ml of water and ethanol mixed solution containing 0.25 wt% of Sodicurlauryl Sulfate, and then emulsified at 25,000 rpm shear stress for 5 minutes. To prepare a suspension. Then, 9 g of the liquid crystal polymer capsule prepared in Example 2 was dispersed in 100 ml of a 0.25 wt% sodicurlauryl sulfate-dissolved water and ethanol mixture, and then a polyvinyl alcohol dispersion stabilizer was added in an amount of 1% based on the total weight. It was. The prepared retinol suspension was added to the solution in which the liquid crystal polymer capsule was dispersed, and reacted at room temperature for 4 hours. The remaining organic solvent was evaporated under reduced pressure, the process of filtration and washing in water was repeated several times, and then dried in a vacuum oven to obtain a capsule in powder form.

<Example 7>

Capsules were prepared in the same manner as in Example 6, except that 10% coenzyme Q-10 based on the total capsule weight was used as the active material.

<Example 8>

A capsule was prepared in the same manner as in Example 6, except that 10% of tocopherol based on the total capsule weight was used as the active material.

Experimental Example 1 Morphology of Capsule

The morphology of the particles prepared in Examples 1 and 2 and Comparative Examples 1 to 3 was observed by an optical microscope. In addition, the phase behavior of the liquid crystal was observed with a polarizing microscope. The results are shown in FIGS. 1 to 4.

In the case of the particles prepared in Comparative Example 1 and Comparative Example 2, the behavior of the liquid crystal was not observed (see FIGS. 3A and 3B). However, in the case of Examples 1-2 and Comparative Example 3 which contain 30 weight% or more of liquid crystals, the phase behavior of a liquid crystal could be observed (FIGS. 1B-2B and 4B).

On the other hand, it can be observed from FIGS. 1 and 2 and 4 that the form of the particles greatly varies depending on the degree of crosslinking. In other words, the cross-linked elastic-shrinkage force is induced by the crosslinking of the polymer phase to cause shrinkage of the liquid crystal / polymeric droplets, and thus, it is likely that the initial spherical shape cannot be maintained, resulting in the deformation of the droplets. However, although the spherical capsule is not formed due to the deformation of the droplet, the crosslinked polymer phase greatly improves the structural stability of the prepared capsule and prevents the outflow of the cholesterol phase located in the inner phase, so that appropriate crosslinking is necessary. In the use of 0.1 to 0.3% by weight crosslinking agent relative to the total amount of the polymer.

Experimental Example 2

The capsules of Examples 2 to 5 were added to the following Formulation Examples 1 to 2 to observe the behavior of the liquid crystals.

<Formulation Example 1>

A solubilized formulation in the form of a transparent gel having the composition of Table 2 was prepared. The viscosity of the formulation is about 3,000 cps. In addition, the viscosity was measured at 30 degreeC 12 rpm using Brookfield (LVDVII +).

ingredient Content (% by weight) glycerin 5 Propylene glycol 4 Liquid Crystal Capsule (Examples 2-5) 5 ethanol 10 Sodium Polyacrylate 0.5 antiseptic Quantity Purified water to 100

<Formulation Example 2>

Each of the oil and water phases in the composition of Table 3 was completely dissolved at 70 ° C., and emulsified at 7,000 rpm for 5 minutes to prepare a lotion in the form of an opaque gel. The viscosity of the lotion is about 2,000 cps.

ingredient Content (% by weight) Stearic acid 2 Cetyl alcohol 2 Lanolin alcohol 2 Liquid paraffin 7 Cyclomethicone 5 Polyoxyethylene monooleic acid ester 2 Preservatives, Antioxidants Quantity glycerin 3 Propylene glycol 5 Triethylamine One Liquid Crystal Capsules (Examples 2-5) 8 Sodium Polyacrylate 0.15 Purified water to 100

As a result, the cholesterol liquid crystal polymethyl methacrylate capsule prepared in Example 2 could not be hydrated in aqueous solution due to the hydrophobicity of the polymethyl methacrylate accumulating the cholesterol liquid crystal, thereby visually confirming the behavior of the liquid crystal in the polymer particles. Could not.

However, the liquid crystal behavior of each of the cholesterol liquid crystal polymer microcapsules prepared in Examples 3 to 5 was observed in each cosmetic composition. Such a visible liquid crystal effect is expected to add specificity to the cosmetic composition and to enhance the product value by making the appearance of the product gorgeous.

Experimental Example 3

To confirm the stability of the active material collected in the liquid crystal polymer capsules prepared in Examples 6 to 8, a cream was prepared in the composition of Table 4 below.

ingredient Content (% by weight) Beads wax 2 Stearyl alcohol 5 Stearic acid 8 Squalane 10 Propylene Glycol Monostearate 3 Polyoxyethylene cetyl ether One Preservatives and Antioxidants Quantity Propylene glycol 8 glycerin 4 Triethylamine One Active substance / liquid crystal capsule (Examples 6-8) 2 Purified water to 100

Each sample was then stored in an oven at 25 ° C. and 40 ° C., after which the sample was taken after a certain period of time to determine the amount of residual active substance using liquid chromatography. The results are shown in Table 5 below.

capsule Storage temperature (℃) Initial concentration retention (%) 1 day later 7 days later 14 days later 28 days later Retinol-containing capsules of Example 6 25 100 99 97 95 50 100 92 91 85 Coenzyme-Q10 Containing Capsule of Example 7 25 100 99 99 99 50 100 99 97 95 Tocopherol-containing capsules of Example 8 25 100 100 99 98 50 100 98 96 94 Retinol 25 100 95 88 73 50 100 83 71 49

As can be seen in Table 5, the retinol, coenzyme Q-10, tocopherol present in the liquid crystal polymer capsule of the present invention was confirmed to exhibit excellent stability in the cosmetic formulation even after long-term storage. These results can be interpreted as showing very high stability because the active ingredient has a high mixing property with the liquid crystal component and has a molecular alignment characteristic similar to the crystal component of the liquid crystal and is fixed in the liquid crystal formation process. . In addition, the polymethyl methacrylate polymer itself, which forms the outer shell layer, has a primary barrier to external stimulation, further improving its stability.

As described above, the thermotropic cholesterol liquid crystal polymer capsule according to the present invention is expected to play an excellent additive role in the cosmetic composition. In particular, since the liquid crystal material is encapsulated in a polymer, the behavior of the liquid crystal can be exhibited as it is, so it can be applied to a smart drug delivery system having a temperature dependence as well as a visual effect of the liquid crystal, and can be expected to be applied as a stabilizing agent. . In addition, it may be variously applied to electronic materials, paint industry, paper industry using the intrinsic liquid crystal behavior of the liquid crystal of the thermotropic liquid crystal by utilizing the external stimulus blocking properties of the polymer phase and excellent compatibility with the general organic material.

Claims (16)

(1) dissolving the thermotropic liquid crystal and monomer in a solvent, and then adding an initiator; (2) adding the solution to an aqueous phase containing a dispersion stabilizer and then emulsifying to obtain an emulsion; (3) adding a polymerization inhibitor to the emulsion, followed by suspension polymerization to obtain a thermotropic liquid crystal polymer capsule. The method of claim 1, wherein in step (1), the crosslinking agent is added in an amount of 0.1 to 0.3% by weight based on the total weight of the polymer. The method of claim 1 or 2, further comprising hydrating the capsule. The method of claim 3, wherein the hydration step is a step of adding a cationic monomer, anionic monomer or hydrophilic monomer to step (1). The method of claim 1 or 2, wherein the thermotropic liquid crystal is a cholesterol and cholesteryl derivative, and is used in an amount of 30 to 50% by weight based on the total capsule particles. 4. The method of claim 3, wherein the thermotropic liquid crystal is a cholesterol and cholesteryl derivative, and is used in an amount of 30 to 50% by weight based on the total capsule particles. The method of claim 5, wherein the cholesteryl derivative is selected from the group consisting of cholesteryl octanoate, cholesteryl nonanoate, cholesteryl oleyl carbonate and cholesteryl isostearyl carbonate Method for producing a liquid crystalline polymer capsule. The method of claim 6, wherein the cholesteryl derivative is selected from the group consisting of cholesteryl octanoate, cholesteryl nonanoate, cholesteryl oleyl carbonate and cholesteryl isostearyl carbonate Method for producing a liquid crystalline polymer capsule. 3. The monomer of claim 1, wherein the monomer is styrene, p- or m-methylstyrene, p- or m-ethylstyrene, p- or m-chlorostyrene, p- or m-chloromethylstyrene, styrenesul Phonic Acid, p- or m- or t-butoxystyrene, methyl (meth) acrylate, ethyl (meth) acrylate, propyl (meth) acrylate, n-butyl (meth) acrylate, isobutyl (meth) Acrylate, t-butyl (meth) acrylate, 2-ethylhexyl (meth) acrylate, n-octyl (meth) acrylate, lauryl (meth) acrylate, stearyl (meth) acrylate, 2-hydrate Oxyethyl (meth) acrylate, polyethylene glycol (meth) acrylate, methoxypolyethylene glycol (meth) acrylate, glycidyl (meth) acrylate, dimethylaminoethyl (meth) acrylate, diethylaminoethyl (meth ) Acrylates, vinyl acetate, vinyl propionate, At least one member selected from the group consisting of nitrile butyrate, vinyl ether, allyl butyl ether, allyl glycidyl ether, (meth) acrylic acid, maleic acid, alkyl (meth) acrylamide and (meth) acrylonitrile. Method for producing a thermotropic liquid crystal polymer capsules, characterized in that used in an amount of 50 to 70% by weight. 4. The monomer of claim 3 wherein the monomer is styrene, p- or m-methylstyrene, p- or m-ethylstyrene, p- or m-chlorostyrene, p- or m-chloromethylstyrene, styrenesulphonic acid, p Or m- or t-butoxystyrene, methyl (meth) acrylate, ethyl (meth) acrylate, propyl (meth) acrylate, n-butyl (meth) acrylate, isobutyl (meth) acrylate, t -Butyl (meth) acrylate, 2-ethylhexyl (meth) acrylate, n-octyl (meth) acrylate, lauryl (meth) acrylate, stearyl (meth) acrylate, 2-hydroxyethyl (meth ) Acrylate, polyethylene glycol (meth) acrylate, methoxy polyethylene glycol (meth) acrylate, glycidyl (meth) acrylate, dimethylaminoethyl (meth) acrylate, diethylaminoethyl (meth) acrylate, Vinyl acetate, vinyl propionate, vinyl butyre 1, at least one selected from the group consisting of vinyl ether, allyl butyl ether, allyl glycidyl ether, (meth) acrylic acid, maleic acid, alkyl (meth) acrylamide and (meth) acrylonitrile. Method for producing a thermotropic liquid crystal polymer capsules, characterized in that used in an amount of 50 to 70% by weight. Cosmetic composition containing a thermotropic liquid crystalline polymer capsule prepared by the method of claim 3. 12. The cosmetic composition of claim 11, wherein the cosmetic product has a formula of softening cream, nourishing cream, massage cream, nutrition cream, pack, gel, essence, lipstick, makeup base, foundation, lotion, ointment, gel, cream, patch and spray. Cosmetic composition, characterized in that. A method for stabilizing an active substance by trapping the active substance in a liquid crystal polymer capsule prepared by the method according to claim 1. A method for stabilizing an active substance by trapping the active substance in a liquid crystal polymer capsule prepared by the method of claim 3. The method of claim 13, wherein the active substance is retinol, retinyl acetate, retinyl palmitate, tocopherol, tocopheryl acetate, tocopheryl linoleate, tocopheryl nicotinate, linoleic acid, coenzyme Q-10, reds A method of stabilizing an active substance, characterized in that it is veratrol or plant extract essential oil. 15. The method of claim 14, wherein the active agent is retinol, retinyl acetate, retinyl palmitate, tocopherol, tocopheryl acetate, tocopheryl linoleate, tocopheryl nicotinate, linoleic acid, coenzyme Q-10, reds A method of stabilizing an active substance, characterized in that it is veratrol or plant extract essential oil.